What Is New in Morphea—Narrative Review on Molecular Aspects and New Targeted Therapies
Journal of Clinical Medicine · 25.11.2024 · 13 (23) · 7134
DOI: 10.3390/jcm13237134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.11.2024. Verfasst von Tomasz Stein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Poznan University of Medical Sciences, 60-806 Poznan, Poland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Morphea, also known as localized scleroderma, is an autoimmune chronic connective tissue disease. It is characterized by excessive collagen deposition in the dermis and/or subcutaneous tissue. The etiopathogenesis of this disease is not fully understood, with endothelial cell damage, immunological disorders, extracellular matrix disorders and factors such as infection, trauma and other autoimmune diseases being considered. As medicine advances, there is increasing evidence that genetic factors play a significant role in disease risk and progression. In addition to environmental factors and genetic predisposition, epigenetic factors may be potential triggers for morphea. Epigenetics studies changes that affect gene expression without altering the DNA sequence, such as microRNAs, long non-coding RNAs or DNA methylation. Understanding the pathogenesis of this disease is key to identifying potential new treatments. There are anecdotal reports of good therapeutic effects following the use of biological drugs such as tocilizumab, a humanized IgG monoclonal antibody; abatacept, a recombinant soluble fusion protein; JAK inhibitors, such as tofacitinib and baricitinib; and a drug used successfully in cancer treatment, imatinib, a tyrosine kinase receptor inhibitor. In this article, we aim to review up-to-date knowledge on the pathogenesis of morphea, with particular emphasis on genetic and epigenetic factors. In addition, we present the new options of morphea treatment based on several case series treated with new drugs that are potential targets for the development of therapies for this disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
- Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
ORCID-Profile: Katarzyna Iżykowska, Monika Pieniawska
Zitieren
APA
Stein, T., Cieplewicz-Guźla, P., Iżykowska, K., Pieniawska, M., Żaba, R., Dańczak-Pazdrowska, A., & Polańska, A. (2024). What Is New in Morphea—Narrative Review on Molecular Aspects and New Targeted Therapies. Journal of Clinical Medicine, 13(23), 7134. https://doi.org/10.3390/jcm13237134
Vancouver
Stein T, Cieplewicz-Guźla P, Iżykowska K, Pieniawska M, Żaba R, Dańczak-Pazdrowska A, et al. What Is New in Morphea—Narrative Review on Molecular Aspects and New Targeted Therapies. Journal of Clinical Medicine. 2024;13(23):7134. doi:10.3390/jcm13237134
BibTeX
@article{Stein2024,
author = {Stein, Tomasz and Cieplewicz-Guźla, Paulina and Iżykowska, Katarzyna and Pieniawska, Monika and Żaba, Ryszard and Dańczak-Pazdrowska, Aleksandra and Polańska, Adriana},
title = {What Is New in Morphea—Narrative Review on Molecular Aspects and New Targeted Therapies},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {23},
pages = {7134},
doi = {10.3390/jcm13237134}
}
EUVIMED